Sage Journals: Discover world-class research

Abstract

Background

Valvular abnormalities are common in antiphospholipid syndrome (APS). For patients who undergo aortic valve replacement (AVR), previous single institutional studies or case reports reported higher risks of mortality and thromboembolic complications among APS patients. This study aimed to investigate in-hospital outcomes of APS patients undergoing transcatheter (TAVR) and surgical aortic valve replacement (SAVR) using the largest all-payer database in the United States.

Methods

Patients who underwent TAVR and SAVR were selected from National Inpatient Sample from Q4 2015-2021. Exclusion criteria were age under 18 years and concomitant procedures. Preoperative characteristics were matched between APS and non-APA patients using a 1:5 propensity-score matching in TAVR and SAVR, separately. In-hospital outcomes were examined.

Results

After propensity-score matching, 504 non-APS patients were matched to 100 APS patients in TAVR, while 581 non-APS patients were matched to 119 APS patients in SAVR. All outcomes between APS and non-APS patients were comparable after TAVR. In contrast, APS patients undergoing SAVR had higher risks of pulmonary embolism (PE; 5.13% vs 0.86%, p < .01) and acute kidney injury (AKI; 35.04% vs 22.55%, p = .01).

Conclusion

This study represents one of the first large-scale, population-based analyses of AVR outcomes for APS patients using a national registry. APS patients had all comparable outcomes after TAVR, while they had higher risks of PE and AKI after SAVR. This highlights the necessity for close perioperative antithrombotic management and careful monitoring of renal function in APS patients. TAVR may offer a safer alternative to SAVR for appropriately selected patients, including those with APS.

Keywords

Aortic stenosis antiphospholipid syndrome surgical aortic valve replacement transcatheter aortic valve replacement valve replacement thromboembolism

Get full access to this article

View all access options for this article.

References

Osnabrugge

RLJ

Mylotte

Head

, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 2013; 62(11): 1002–1012.

Smith

Leon

Mack

, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364(23): 2187–2198.

Leon

Smith

Mack

, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374(17): 1609–1620.

Luo

Yanavitski

, et al. Disparity among Asian Americans in transcatheter and surgical aortic valve replacement. Cardiovasc Revascularization Med. 2023; 59: 84–90. Available from: https://www.sciencedirect.com/science/article/pii/S1553838923007984

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2): 295–306.

Cervera

. Antiphospholipid syndrome. Thromb Res 2017; 151(Suppl 1): S43–S47.

Lockshin

Tenedios

Petri

, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003; 12(7): 518–523.

, et al. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol [Internet] 2019; 10: 941. Available from: https://pubmed.ncbi.nlm.nih.gov/31134062/

Tincani

Rebaioli

Taglietti

, et al. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology 2006; 45(Suppl 4): iv8–13.

10.

Amigo

. What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? Lupus 2014; 23(12): 1259–1261.

11.

Eviatar

Niznik

Elkayam

, et al. Heart valve surgery in antiphospholipid syndrome patients—morbidity and mortality. Life [Internet]. 2023; 13(4): 891. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146753/

12.

Hojnik

George

Ziporen

, et al. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996; 93(8): 1579–1587.

13.

Kampolis

Tektonidou

Moyssakis

, et al. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. Semin Arthritis Rheum 2014; 43(4): 558–565.

14.

Nesher

Ilany

Rosenmann

, et al. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997; 27(1): 27–35.

15.

Berkun

Elami

Meir

, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg 2004; 127(2): 414–420.

16.

Colli

Mestres

Espinosa

, et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardio Thorac Surg 2010; 37(1): 154–158.

17.

Endara

Dávalos

Fierro

, et al. Antiphospholipid syndrome and valvular heart disease, a complex scenario of thrombotic events, a case report. J Cardiothorac Surg 2020; 15(1): 275.

18.

Erdozain

Ruiz-Irastorza

Segura

, et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res 2012; 64(8): 1256–1260.

19.

Hogan

McBane

Santrach

, et al. Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc 2000; 75(9): 971–976.

20.

Hoshi

Hiraya

Sato

, et al. Potential risk of perioperative thromboembolism in patients with antiphospholipid syndrome who undergo transcatheter aortic valve implantation: a case series. Cathet Cardiovasc Interv 2021; 98(2): E315–E319.

21.

, et al. Transcatheter aortic valve replacement for advanced valvular disease in active SLE and APS. Lupus [Internet] 2013; 22(10): 1046–1049. Available from: https://pubmed.ncbi.nlm.nih.gov/23884983/

22.

Pons

Louro

Sitges

, et al. Heart valve involvement in patients with antiphospholipid syndrome: a long-term follow-up study of a single centre. J Clin Med 2023; 12(8): 2996.

23.

Elixhauser

Steiner

Harris

, et al. Comorbidity measures for use with administrative data. Med Care 1998; 36(1): 8–27.

24.

Petri

. Antiphospholipid syndrome. Transl Res 2020; 225: 70–81.

25.

Reverter

Tàssies

Font

, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996; 16(11): 1319–1326.

26.

Majdan

. Kidney involvement in antiphospholipid syndrome – current diagnostic and management problems. Reumatologia 2017; 55(5): 213–214.

27.

Turrent-Carriles

Herrera-Félix

Amigo

. Renal involvement in antiphospholipid syndrome. Front Immunol 2018; 9: 1008.

28.

Bell

Ross

Zealley

, et al. Management of post-operative acute kidney injury. QJM: Int J Med 2017; 110(11): 695–700.

29.

ACSD operative risk calculator | STS

[Internet]. [cited 2023 Oct 23]. Available from: https://www.sts.org/resources/acsd-operative-risk-calculator

30.

Nashef

SAM

Roques

Sharples

, et al. EuroSCORE II. Eur J Cardio Thorac Surg 2012; 41(4): 734–744, ; discussion 744-745.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.47 MB

In-hospital outcomes of patients with antiphospholipid syndrome undergoing transcatheter and surgical aortic valve replacement: A population-based analysis of national inpatient sample from 2015–2021